Co-Diagnostics (CODX) Competitors $0.25 -0.01 (-4.02%) Closing price 08/1/2025 03:56 PM EasternExtended Trading$0.25 0.00 (-0.89%) As of 08/1/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CODX vs. PYPD, POCI, COCH, PSTV, VVOS, CLGN, FEMY, DRIO, IRIX, and ALURShould you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include PolyPid (PYPD), Precision Optics (POCI), Envoy Medical (COCH), Plus Therapeutics (PSTV), Vivos Therapeutics (VVOS), CollPlant Biotechnologies (CLGN), Femasys (FEMY), DarioHealth (DRIO), IRIDEX (IRIX), and Allurion Technologies (ALUR). These companies are all part of the "medical equipment" industry. Co-Diagnostics vs. Its Competitors PolyPid Precision Optics Envoy Medical Plus Therapeutics Vivos Therapeutics CollPlant Biotechnologies Femasys DarioHealth IRIDEX Allurion Technologies PolyPid (NASDAQ:PYPD) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment. Is PYPD or CODX more profitable? PolyPid has a net margin of 0.00% compared to Co-Diagnostics' net margin of -1,025.45%. Co-Diagnostics' return on equity of -60.16% beat PolyPid's return on equity.Company Net Margins Return on Equity Return on Assets PolyPidN/A -1,069.37% -151.85% Co-Diagnostics -1,025.45%-60.16%-52.69% Which has more risk and volatility, PYPD or CODX? PolyPid has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Do analysts prefer PYPD or CODX? PolyPid presently has a consensus price target of $11.80, suggesting a potential upside of 246.04%. Co-Diagnostics has a consensus price target of $5.50, suggesting a potential upside of 2,115.95%. Given Co-Diagnostics' higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than PolyPid.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Co-Diagnostics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in PYPD or CODX? 26.5% of PolyPid shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 8.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable earnings & valuation, PYPD or CODX? PolyPid has higher earnings, but lower revenue than Co-Diagnostics. PolyPid is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolyPidN/AN/A-$29.02M-$4.30-0.79Co-Diagnostics$3.91M2.13-$37.64M-$1.17-0.21 Does the media prefer PYPD or CODX? In the previous week, Co-Diagnostics had 1 more articles in the media than PolyPid. MarketBeat recorded 2 mentions for Co-Diagnostics and 1 mentions for PolyPid. PolyPid's average media sentiment score of 0.00 equaled Co-Diagnostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPolyPid and Co-Diagnostics tied by winning 7 of the 14 factors compared between the two stocks. Get Co-Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CODX vs. The Competition Export to ExcelMetricCo-DiagnosticsMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.68M$7.18B$5.47B$9.53BDividend YieldN/A2.90%4.74%4.08%P/E Ratio-0.2164.1328.6723.80Price / Sales2.1334.23422.3188.12Price / CashN/A25.7735.4557.96Price / Book0.158.618.275.55Net Income-$37.64M$239.96M$3.24B$259.03M7 Day Performance-11.36%-5.48%-3.63%-4.56%1 Month Performance-13.22%-3.73%4.40%4.49%1 Year Performance-77.23%18.27%25.97%18.05% Co-Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CODXCo-Diagnostics3.7739 of 5 stars$0.25-4.0%$5.50+2,116.0%-77.6%$8.68M$3.91M-0.21100News CoveragePositive NewsUpcoming EarningsShort Interest ↑PYPDPolyPid2.265 of 5 stars$3.64-1.1%$11.80+224.2%-6.6%$37.50MN/A-0.8580POCIPrecision Optics0.1924 of 5 stars$4.70-2.1%N/A-23.8%$36.80M$19.10M-5.2880Gap UpCOCHEnvoy Medical1.9169 of 5 stars$1.53-1.9%$9.25+504.6%-37.2%$33.27M$220K-1.1134News CoveragePositive NewsEarnings ReportPSTVPlus Therapeutics2.1804 of 5 stars$0.58+9.4%$10.83+1,768.8%-67.5%$32.05M$5.82M-0.2020Gap UpVVOSVivos Therapeutics0.6854 of 5 stars$4.72-9.9%$4.82+2.0%+138.7%$30.86M$14.63M-2.73160Short Interest ↑Gap DownCLGNCollPlant Biotechnologies2.1216 of 5 stars$2.33+0.9%$11.50+393.6%-48.3%$29.37M$510K-1.9170Positive NewsFEMYFemasys2.7596 of 5 stars$0.87-3.9%$8.67+901.8%-27.5%$29.27M$1.63M-0.9530High Trading VolumeDRIODarioHealth1.431 of 5 stars$0.63-4.0%$2.00+219.9%-47.1%$28.95M$27.04M-1.12200Upcoming EarningsIRIXIRIDEX0.4788 of 5 stars$1.53+8.5%N/A-36.3%$23.67M$48.67M-3.56120Upcoming EarningsGap UpHigh Trading VolumeALURAllurion Technologies2.1301 of 5 stars$3.03+0.2%$22.83+654.8%-87.5%$22.52M$28.30M-0.24501 Related Companies and Tools Related Companies PYPD Competitors POCI Competitors COCH Competitors PSTV Competitors VVOS Competitors CLGN Competitors FEMY Competitors DRIO Competitors IRIX Competitors ALUR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CODX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Co-Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Co-Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
